Olyos Group

Headquartered in France, Olyos Group is an international pharmaceutical entity specializing in holistic health solutions, focusing on natural ingredients to improve family health across various domains. Olyos Group, formed in 1948, operates within the pharmaceutical sector, emphasizing natural health and nutrition. The company has retained its core mission without notable pivots and does not have publicly mentioned subsidiaries. It is led by founders with experience in health-related ventures, establishing a strong footprint in over 60 countries.

Olyos is an international pharmaceutical group specializing in natural health and nutrition, offering a diverse range of products designed to meet the health needs of families. Their core product offerings include medications, dietary supplements, natural cosmetics, and nutritional solutions, all developed with a focus on natural ingredients and holistic health principles. The company emphasizes the use of essential trace elements and natural components, adhering to pharmaceutical standards throughout the product development process, from conception to market release. Olyos caters to various specific health domains such as dermatology, pain relief, gynecology, rheumatology, stress management, fertility, weight management, vitality, and sports nutrition.

The products are marketed across numerous geographical regions, including over 60 countries in Europe, North America, South America, Africa, and Asia, ensuring accessibility to a global consumer base that includes healthcare professionals and end-users seeking effective natural health solutions. Olyos generates revenue primarily through the sale of its health solutions via pharmacies and e-commerce platforms, establishing a robust distribution network. Transactions typically occur through partnerships with pharmacies and healthcare providers, allowing for direct sales to consumers while also facilitating access through retail channels. The company’s revenue streams include individual product sales as well as potential subscription models for continuous supply of health supplements.

The flagship product lines, including those from their brands such as Laboratoire des Granions, Eafit, and Drasanvi, contribute significantly to their market presence. While specific pricing structures for individual products are not disclosed, Olyos maintains a strong competitive position in the natural health market, bolstered by the trust of healthcare professionals and the loyalty of consumers both domestically and internationally. In June 2025, Motion Equity Partners moved the company to Motion Continuity II fund from its intial investment in 2017. The company plans to introduce new product lines targeting unmet health needs and aims to expand its market presence into Asia and Africa by the end of 2025.

The recent funding will be utilized to enhance product development and marketing efforts in these new regions.